ToleRability of BevacizUmab in elderly Ovarian cancer patients (TURBO study): a case-control study of a real-life experience

Author: Giulia AMADIO ¹ ; Claudia MARCHETTI ; Emanuele Rocco VILLANI ; Domenico FUSCO ; Francesca STOLLAGLI ; Carolina BOTTONI ; Mariagrazia DISTEFANO ; Giuseppe COLLOCA ; Giovanni SCAMBIA ; Anna FAGOTTI
Author Information

1. Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy. clamarchetti@libero.it
Publication Type:Original Article
Keywords: Ovarian Cancer; Bevacizumab; Toxicity; Elderly; Chemotherapy
MeSH: Aged; Bevacizumab; Case-Control Studies; Comorbidity; Creatinine; Diagnosis; Drug Therapy; Female; Glomerular Filtration Rate; Humans; Logistic Models; Ovarian Neoplasms
From:Journal of Gynecologic Oncology 2020;31(1):6-
CountryRepublic of Korea
Language:English
Abstract: 1.1 g/dL, estimated glomerular filtration rate (eGFR) ≤60 mL/min, ≥3 comorbidities were independently associated with a higher severe toxicity.CONCLUSIONS: Elderly patients with EOC can safely be treated with bevacizumab; factors other than age, as higher creatinine serum levels, eGFR and number of comorbidities should be considered to better estimate bevacizumab-related toxicity risk.]]>